The occurrence and curing of stuttering during the use of methylphenidate for ADHD in childhood : An inconsistent relationship
Year 2023,
, 291 - 293, 31.12.2023
Tayfun Kara
,
Fahri Çelebi
Abstract
Stuttering is a childhood onset fluency disorder in speech. It has been suggested to be associated with brain anatomy, functionality or the dysregulation of the dopaminergic activity. Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in childhood and adolescence. Psychostimulant medications are widely used for the psychopharmacologic treatment of ADHD. In this article, two boys who have ADHD with opposite reactions after methylphenidate (MPH) treatment in terms of fluency in the speech are presented. In the first case stuttering was induced with MPH while in the second case stuttering was resolved after MPH treatment. Although MPH seems to have opposite effects on stuttering in our cases, our case report points that dopaminergic system may play a role for the onset of childhood onset fluency disorder. More comprehensive studies are needed to show the neurodevelopmental process and the mechanisms related with ADHD, stuttering and MPH treatment.
References
- 1. Perez HR, Stoeckle JH. Stuttering: Clinical and research update. Can Fam Physician. 2016; 62:479-84. PMID: 27303004
- 2. Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord. 2013; 38:66-87. doi: 10.1016/j.jfludis.2012.11.002
- 3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Arlington (VA): American Psychiatric Publishing; 2013. doi: 10.1176/appi.books.9780890425596
- 4. Smith A, Weber C. How Stuttering Develops: The Multifactorial Dynamic Pathways Theory. J Speech Lang Hear Res. 2017; 60:2483-2505. doi: 10.1044/2017_JSLHR-S-16-0343
- 5. Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis. 2012; 5:1-17. doi: 10.4137/JCNSD.S6691
- 6. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014; 48:209-25. doi: 10.1177/1060028013510699
- 7. Trenque T, Claustre G, Herlem E, et al. Methylphenidate and stuttering. Br J Clin Pharmacol. 2019;85(11):2634-2637. doi: 10.1111/bcp.14097
- 8. Alpaslan AH, Coşkun KŞ, Kocak U, Gorücü Y. Stuttering Associated With the Use of Short-Acting Oral Methylphenidate. J Clin Psychopharmacol. 2015; 35:739-41. doi: 10.1097/JCP.0000000000000403
- 9. Rabaeys H, Bijleveld HA, Devroey D. Influence of Methylphenidate on the Frequency of Stuttering: A Randomized Controlled Trial. Ann Pharmacother. 2015; 49:1096-104. doi: 10.1177/1060028015596415
- 10. Devroey D, Beerens G, Van De Vijver E. Methylphenidate as a treatment for stuttering: a case report. Eur Rev Med Pharmacol Sci. 2012; 16:66-9. PMID: 23090813
- 11. Louis ED, Winfield L, Fahn S, Ford B. Speech dysfluency exacerbated by levodopa in Parkinson's disease. Mov Disord. 2001; 16:562-5. doi: 10.1002/mds.1081
- 12. McAllister MW, Woodhall DM. Bupropion-induced stuttering treated with haloperidol. Clin Toxicol (Phila). 2016; 54:603. doi: 10.1080/15563650.2016.1179749
- 13. Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering. Neuroreport. 1997; 8:767-70. doi: 10.1097/00001756-199702100-00037
- 14. Mulligan HF, Anderson TJ, Jones RD, Williams MJ, Donaldson IM. Tics and developmental stuttering. Parkinsonism Relat Disord. 2003; 9:281-9. doi: 10.1016/s1353-8020(03)00002-6
- 15. Chang SE. Research updates in neuroimaging studies of children who stutter. Semin Speech Lang. 2014; 35:67–79. doi: 10.1055/s-0034-1382151
- 16. Hoang JL, Patel S, Maguire GA. Case report of aripiprazole in the treatment of adolescent stuttering. Ann Clin Psychiatry. 2016; 28:64-5. PMID: 27500298
- 17. Lavid N, Franklin DL, Maguire GA. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry. 1999; 11:233-6. doi: 10.1023/a:1022365513865
- 18. Murphy R, Gallagher A, Sharma K, Ali T, Lewis E, Murray I, Hallahan B. Clozapine-induced stuttering: an estimate of prevalence in the west of Ireland.Ther Adv Psychopharmacol. 2015; 5:232-6. doi: 10.1177/2045125315590060
- 19. Bär KJ, Häger F, Sauer H. Olanzapine- and clozapine-induced stuttering. A case series. Pharmacopsychiatry. 2004; 37:131-4. doi: 10.1055/s-2004-818992
- 20. Yadav DS. Risperidone induced stuttering. Gen Hosp Psychiatry. 2010; 32:559.e9-10. doi: 10.1016/j.genhosppsych.2010.01.004
- 21. Druker K, Hennessey N, Mazzucchelli T, Beilby J. Elevated attention deficit hyperactivity disorder symptoms in children who stutter. J Fluency Disord. 2019;59:80-90. doi: 10.1016/j.jfludis.2018.11.002
Çocukluk çağında DEHB tanısı ile metilfenidat kullanımı sırasında ortaya çıkan ve sonlanan kekemelik: Tutarsız bir ilişki
Year 2023,
, 291 - 293, 31.12.2023
Tayfun Kara
,
Fahri Çelebi
Abstract
Kekemelik çocukluk döneminde başlayan konuşmada akıcılık bozukluğudur. Beyin anatomisi, işlevselliği veya dopaminerjik aktivitenin düzensizliği ile ilişkili olduğu öne sürülmüştür. Dikkat eksikliği hiperaktivite bozukluğu (DEHB), çocukluk ve ergenlik döneminde en sık görülen psikiyatrik bozukluklardan biridir. DEHB'nin psikofarmakolojik tedavisinde psikostimülan ilaçlar yaygın olarak kullanılmaktadır. Bu makalede, metilfenidat (MPH) tedavisi sonrası konuşma akıcılığı açısından birbirine zıt tepkiler veren DEHB'li iki erkek çocuk sunulmaktadır. İlk vakada kekemelik MPH ile indüklenirken, ikinci vakada kekemelik MPH tedavisinden sonra çözüldü. Olgularımızda MPH'nin kekemelik üzerinde birbirine zıt etkileri varmış gibi görünmektedir, olgu sunumumuz çocukluk çağı başlangıçlı akıcılık bozukluğunun ortaya çıkmasında dopaminerjik sistemin rol oynayabileceğine işaret etmektedir. DEHB, kekemelik ve MPH tedavisi ile ilgili nörogelişimsel süreci ve mekanizmaları göstermek için daha kapsamlı çalışmalara ihtiyaç vardır.
References
- 1. Perez HR, Stoeckle JH. Stuttering: Clinical and research update. Can Fam Physician. 2016; 62:479-84. PMID: 27303004
- 2. Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord. 2013; 38:66-87. doi: 10.1016/j.jfludis.2012.11.002
- 3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Arlington (VA): American Psychiatric Publishing; 2013. doi: 10.1176/appi.books.9780890425596
- 4. Smith A, Weber C. How Stuttering Develops: The Multifactorial Dynamic Pathways Theory. J Speech Lang Hear Res. 2017; 60:2483-2505. doi: 10.1044/2017_JSLHR-S-16-0343
- 5. Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis. 2012; 5:1-17. doi: 10.4137/JCNSD.S6691
- 6. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014; 48:209-25. doi: 10.1177/1060028013510699
- 7. Trenque T, Claustre G, Herlem E, et al. Methylphenidate and stuttering. Br J Clin Pharmacol. 2019;85(11):2634-2637. doi: 10.1111/bcp.14097
- 8. Alpaslan AH, Coşkun KŞ, Kocak U, Gorücü Y. Stuttering Associated With the Use of Short-Acting Oral Methylphenidate. J Clin Psychopharmacol. 2015; 35:739-41. doi: 10.1097/JCP.0000000000000403
- 9. Rabaeys H, Bijleveld HA, Devroey D. Influence of Methylphenidate on the Frequency of Stuttering: A Randomized Controlled Trial. Ann Pharmacother. 2015; 49:1096-104. doi: 10.1177/1060028015596415
- 10. Devroey D, Beerens G, Van De Vijver E. Methylphenidate as a treatment for stuttering: a case report. Eur Rev Med Pharmacol Sci. 2012; 16:66-9. PMID: 23090813
- 11. Louis ED, Winfield L, Fahn S, Ford B. Speech dysfluency exacerbated by levodopa in Parkinson's disease. Mov Disord. 2001; 16:562-5. doi: 10.1002/mds.1081
- 12. McAllister MW, Woodhall DM. Bupropion-induced stuttering treated with haloperidol. Clin Toxicol (Phila). 2016; 54:603. doi: 10.1080/15563650.2016.1179749
- 13. Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering. Neuroreport. 1997; 8:767-70. doi: 10.1097/00001756-199702100-00037
- 14. Mulligan HF, Anderson TJ, Jones RD, Williams MJ, Donaldson IM. Tics and developmental stuttering. Parkinsonism Relat Disord. 2003; 9:281-9. doi: 10.1016/s1353-8020(03)00002-6
- 15. Chang SE. Research updates in neuroimaging studies of children who stutter. Semin Speech Lang. 2014; 35:67–79. doi: 10.1055/s-0034-1382151
- 16. Hoang JL, Patel S, Maguire GA. Case report of aripiprazole in the treatment of adolescent stuttering. Ann Clin Psychiatry. 2016; 28:64-5. PMID: 27500298
- 17. Lavid N, Franklin DL, Maguire GA. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry. 1999; 11:233-6. doi: 10.1023/a:1022365513865
- 18. Murphy R, Gallagher A, Sharma K, Ali T, Lewis E, Murray I, Hallahan B. Clozapine-induced stuttering: an estimate of prevalence in the west of Ireland.Ther Adv Psychopharmacol. 2015; 5:232-6. doi: 10.1177/2045125315590060
- 19. Bär KJ, Häger F, Sauer H. Olanzapine- and clozapine-induced stuttering. A case series. Pharmacopsychiatry. 2004; 37:131-4. doi: 10.1055/s-2004-818992
- 20. Yadav DS. Risperidone induced stuttering. Gen Hosp Psychiatry. 2010; 32:559.e9-10. doi: 10.1016/j.genhosppsych.2010.01.004
- 21. Druker K, Hennessey N, Mazzucchelli T, Beilby J. Elevated attention deficit hyperactivity disorder symptoms in children who stutter. J Fluency Disord. 2019;59:80-90. doi: 10.1016/j.jfludis.2018.11.002